20:24 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

Omeros Corp. (NASDAQ:OMER) reported data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for 12 weeks led to a 0.4% greater reduction in median proteinuria...
23:38 , Oct 2, 2018 |  BC Extra  |  Clinical News

Omeros' OMS721 underwhelms in Phase II

Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721...
22:10 , Aug 3, 2018 |  BC Extra  |  Politics & Policy

ICER announces preliminary 2019 topics

The Institute for Clinical and Economic Review (ICER) released Thursday a preliminary list of drugs and other healthcare interventions that it may review in 2019. ICER's selection criteria include the projected timing and likelihood of...
21:08 , Aug 2, 2018 |  BC Extra  |  Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes...
16:13 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Omeros reports Phase II OS data for OMS721 in thrombotic microangiopathy

Omeros Corp. (NASDAQ:OMER) reported data from 18 patients with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (HCT-TMA) in a Phase II trial and one HCT-TMA patient treated under a compassionate use program showing that once-weekly...
22:19 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Omeros to start Phase III trial of OMS721 to treat IgA nephropathy

Omeros Corp. (NASDAQ:OMER) said it reached an agreement with FDA on the design of a Phase III trial to test OMS721 in patients with IgA nephropathy. The company expects to begin enrollment early February. The double-blind,...
23:02 , Nov 10, 2017 |  BC Extra  |  Company News

Omeros soars on single Phase III plan for OMS721

Omeros Corp. (NASDAQ:OMER) soared $4.08 (29%) to $18.17 Friday after announcing late Thursday that FDA will accept a single Phase III trial with a primary endpoint of proteinuria reduction to support approval of OMS721 to...
19:51 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Omeros raises $68.3M in follow-on

On Aug. 15, Omeros Corp. (NASDAQ:OMER) raised $68.3 million through the sale of 3 million shares at $22.75 in a follow-on underwritten by Cantor Fitzgerald, H.C. Wainwright, JonesTrading Institutional Services and Maxim Group. Omeros' OMS721 is...
21:03 , Aug 15, 2017 |  BC Extra  |  Financial News

Omeros, Oxford Immunotec fall after pricing follow-ons

Shares of Omeros Corp. (NASDAQ:OMER) and Oxford Immunotec Global plc (NASDAQ:OXFD) both slipped on Tuesday after the companies priced follow-ons, raising over $108 million total. Omeros raised $68.3 million through the sale of 3 million shares...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc.’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4, the advocacy...